Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
TV & Film
History
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/92/50/e6/9250e60f-3130-bac4-4873-ee822cd0a82b/mza_8753601058137276188.jpg/600x600bb.jpg
The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest
The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest
22 episodes
2 weeks ago
Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.
Show more...
Life Sciences
Science
RSS
All content for The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest is the property of The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.
Show more...
Life Sciences
Science
https://audioboom.com/i/43133484.jpg
18: The Adipokine Hypothesis and Inflammation: Explaining Pathogenesis and Guiding Treatment
The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest
30 minutes
2 months ago
18: The Adipokine Hypothesis and Inflammation: Explaining Pathogenesis and Guiding Treatment
Prior to the 2025 American Heart Association (AHA) Scientific Sessions Meeting, Craig J. Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, discusses two recent papers that are influencing practice within the cardiovascular space.
The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest
Craig Beavers and Kyle Fischer, PharmD, BCCP, MBA, discuss key late-breaking cardiovascular trials expected at the American Heart Association’s upcoming annual meeting, exploring their clinical relevance and implications for pharmacists.